Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Cardiovascular Diabetology|March 2, 2011
Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalenceMichel P Hermans, Frank M Sacks, Sylvie A Ahn, et al.
Diabetes & Metabolic Syndrome|September 16, 2014
Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetesSoumaïla Camara, Evariste Bouenizabila, Michel P Hermans, et al.
Lancet (London, England)|June 6, 2003
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up studyPhilip Jong, Salim Yusuf, Michel F Rousseau, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 14, 2016
Sflt-1 in heart failure: relation with disease severity and biomarkersDamien Gruson, Michel P Hermans, Benjamin Ferracin, et al.
EJIFCC|July 17, 2023
CA125, Galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fractionDamien Gruson, Diane Maisin, Anne-Catherine Pouleur, et al.
Complementary Therapies in Medicine|November 21, 2017
Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgiaChristian Tshongo Muhindo, Sylvie A Ahn, Michel F Rousseau, et al.
Annales D'Endocrinologie|November 3, 2021
Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?Damien Gruson, Anne-Catherine Pouleur, Michel P Hermans, et al.
Acta Cardiologica|June 27, 2025
Cross-prevalence of large and small vessels disease in T2DM: overview from a Belgian academic centreFabian O Lurquin, Elise L Petit, Sylvie A Ahn, et al.
Cardiovascular Diabetology|May 21, 2015
Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studiesMichel P Hermans, Evariste Bouenizabila, Daniel K Amoussou-Guenou, et al.
Peptides|August 21, 2012
C-terminal FGF23 is a strong predictor of survival in systolic heart failureDamien Gruson, Thibault Lepoutre, Jean-Marie Ketelslegers, et al.
Pageof 6